SCHEMBL24709151

SCHEMBL24709151

CCCOCCOCCOCCOCCNC(=O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
TDP1 Q9NUW8 1/20 0.49
KDM4E B2RXH2 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
SIGMAR1 Q99720 3/20 0.39
EPHX2 P34913 1/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29300493 1.00 ALDH1A1 (0.49) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL29300492 1.00 ALDH1A1 (0.49) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL29300494 0.98 ALDH1A1 (0.50) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL7127556 0.92 ALDH1A1 (0.51) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL27331967 0.92 ALDH1A1 (0.47) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL23153012 0.92 ALDH1A1 (0.51) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL24709383 0.92 ALDH1A1 (0.47) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL13474979 0.91 ALDH1A1 (0.50) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL17971051 0.90 ALDH1A1 (0.50) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL29302068 0.90 ALDH1A1 (0.43) ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129614-A1 SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2024-06-20 WO disclosed
WO-2022261221-A1 NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2022-12-15 WO disclosed